Cyclerion Therapeutics (NASDAQ:KRSA) Stock Jumps 5.2% – Here’s Why

Shares of Cyclerion Therapeutics, Inc. (NASDAQ:KRSA – Get Free Report) shot up 5.2% on Monday. The stock traded as high as $33.42 and last traded at $33.30. 29,911 shares changed hands during trading, a decline of 89% from the average session volume of 276,293 shares. The stock had previously closed at $31.65.

Analyst Ratings Changes

KRSA has been the topic of several recent analyst reports. Wells Fargo & Company assumed coverage on shares of Cyclerion Therapeutics in a research note on Friday. They issued an “overweight” rating and a $44.00 price target on the stock. Guggenheim began coverage on shares of Cyclerion Therapeutics in a report on Monday, September 28th. They issued a “buy” rating and a $70.00 target price for the company. Stifel Nicolaus began coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They issued a “buy” rating and a $43.00 target price on the stock. Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. Finally, Wedbush began coverage on shares of Cyclerion Therapeutics in a research report on Monday, October 5th. They issued an “outperform” rating and a $44.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.20.

View Our Latest Report on Cyclerion Therapeutics

Cyclerion Therapeutics Trading Up 3.4%

The business’s 50 day moving average is $32.07. The stock has a market cap of $1.49 billion, a P/E ratio of -2.58 and a beta of 1.85.

Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($3.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($50.40) by $47.21. On average, research analysts expect that Cyclerion Therapeutics, Inc. will post -5.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Cyclerion Therapeutics in the second quarter valued at $57,000. Braidwell LP purchased a new stake in shares of Cyclerion Therapeutics in the second quarter valued at about $532,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Cyclerion Therapeutics during the second quarter worth about $1,013,000. 75.62% of the stock is owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics was a clinical-stage biotechnology company focused on developing medicines for serious disorders of the central nervous system. The company originated as a spinout from Ironwood Pharmaceuticals in 2019 and was based in Cambridge, Massachusetts. Its research centered on small-molecule drugs that stimulate soluble guanylate cyclase, an enzyme involved in cellular signaling. Cyclerion’s development portfolio included zagociguat, an investigational, brain-penetrant candidate studied for conditions including cognitive impairment associated with Alzheimer’s disease and other neurological disorders.

Featured Stories

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.